Jun 2026 (Q2 FY26) — Aug 6, 2026
Horace Mann Q2 FY26 — Record Core Earnings and Raised Full-Year Guidance
Read the full callHorace Mann (HMN) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Horace Mann earnings: last reported Thu, 6 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 444 | +7.7% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | Operating profit / revenue | Quarter to Jun 2026 | Not in the filed figures for the quarter to jun 2026. No older figure is substituted. | ||
| Net profit | 41.6 | +41.5% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Price
$46.29 −0.09% · −$0.04
Performance +5.2% 1Y
1Y: $43.99 on 17 Oct 2025 → $46.29. High $54.12 (6 Jul 2026), low $41.49 (20 Mar 2026).
- Previous close
- $46.33
- 52-week range
- $41.49 – $54.12
- One year
- +4.63%
Overview
- Symbol
- HMN
- Sector
- Financials
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Horace Mann earnings calls (HMN)
Financials
What the filings say
Net profit, year on year: +41% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 412 | 409 | 416 | 412 | 439 | 435 | 429 | 444 |
| Interest | 9 | 9 | 9 | 9 | 9 | 10 | 10 | 10 |
| Profit before tax | 43 | 48 | 48 | 37 | 72 | 46 | 50 | 49 |
| Tax rate | 19.7% | 20.9% | 19.6% | 19.4% | 18.5% | 20.8% | 17.9% | 15.1% |
| Net profit | 34 | 38 | 38 | 29 | 58 | 36 | 41 | 42 |
| EPS ($ per share) | 0.83 | — | 0.93 | 0.71 | 1.42 | — | 1.01 | 1.02 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | 1,217 | 1,353 | 1,435 | 1,525 | 1,512 | 1,502 | 1,548 | 1,652 |
| Total liabilities | 9,741 | 10,911 | 11,682 | 12,577 | 12,208 | 12,875 | 13,200 | 13,784 |
| Fixed assets | 41 | 60 | 65 | 66 | 69 | 69 | 73 | 71 |
| Total assets | 11,032 | 12,479 | 13,472 | 14,460 | 13,306 | 14,050 | 14,488 | 15,267 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 201 | 128 | 260 | 205 | 172 | 302 | 452 | 553 |
| Cash from investing | -186 | 56 | -407 | -302 | -215 | -107 | -136 | -252 |
| Cash from financing | -10 | -170 | 144 | 209 | -48 | -208 | -308 | -312 |
| Net cash flow | 4 | 14 | -3 | 111 | -91 | -13 | 8 | -11 |
Insider filings
56 filings between Nov 3, 2025 and Oct 8, 2026.
Open market
decisions to buy or sellPurchases
$157.2K
2 purchases by 2 insiders
Sales
$3.86M
24 sales by 7 insiders
75% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 25
- Award — granted as compensation
- 2
- Option exercise — converted options into shares
- 2
- Tax withheld — shares kept back by the company to cover tax
Also filed: 1 gift.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| ZURAITIS MARITA | — | $2.91M | Oct 8, 2026 |
| BRADLEY THOMAS A | — | $258.6K | Aug 12, 2026 |
| Hines Perry G. | — | $169.0K | Sep 3, 2026 |
| Fetter Victor | $149.5K | — | Feb 25, 2026 |
| McClure Beverley J. | — | $143.9K | Apr 1, 2026 |
| Desrochers Mark R | — | $141.0K | Nov 21, 2025 |
| Reece Henry Wade | — | $129.6K | Aug 12, 2026 |
| Carley Donald M | — | $107.4K | Sep 3, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 8, 2026 | ZURAITIS MARITA President & CEO | Sale 10b5-1 plan | 550 | $25.3K |
| Oct 6, 2026 | ZURAITIS MARITA President & CEO | Sale 10b5-1 plan | 100 | $4.6K |
| Sep 3, 2026 | Hines Perry G. Director | Sale | 3,237 | $169.0K |
| Sep 3, 2026 | Carley Donald M General Counsel | Sale | 2,054 | $107.4K |
| Sep 1, 2026 | ZURAITIS MARITA President & CEO | Sale 10b5-1 plan | 7,500 | $382.4K |
| Aug 12, 2026 | BRADLEY THOMAS A Director | Sale | 5,000 | $258.6K |
| Aug 12, 2026 | Reece Henry Wade Director | Sale | 1,359 | $70.0K |
| Aug 3, 2026 | ZURAITIS MARITA President & CEO | Sale 10b5-1 plan | 7,500 | $390.2K |
| Jul 1, 2026 | ZURAITIS MARITA President & CEO | Sale 10b5-1 plan | 7,500 | $394.6K |
| Jun 24, 2026 | ZURAITIS MARITA President & CEO | Option exercise 10b5-1 plan | 71,532 | $3.07M |
| Jun 24, 2026 | ZURAITIS MARITA President & CEO | Tax withheld 10b5-1 plan | 63,678 | $3.23M |
| Jun 24, 2026 | ZURAITIS MARITA President & CEO | Option exercise 10b5-1 plan | 70,424 | $2.95M |
| Jun 24, 2026 | ZURAITIS MARITA President & CEO | Tax withheld 10b5-1 plan | 65,465 | $3.32M |
| Jun 2, 2026 | ZURAITIS MARITA President & CEO | Sale 10b5-1 plan | 7,500 | $346.8K |
| May 20, 2026 | Sarsynski Elaine A Director | Award | 2,780 | $130.0K |
| May 20, 2026 | Reece Henry Wade Director | Award | 2,780 | $130.0K |
| May 20, 2026 | McClure Beverley J. Director | Award | 2,780 | $130.0K |
| May 20, 2026 | KONEN MARK E Director | Award | 2,780 | $130.0K |
| May 20, 2026 | BRADLEY THOMAS A Director | Award | 2,780 | $130.0K |
| May 20, 2026 | Samuel Aaliyah A Director | Award | 2,780 | $130.0K |
| May 20, 2026 | Fetter Victor Director | Award | 2,780 | $130.0K |
| May 20, 2026 | Fetter Victor Director | Award | 1,176 | $55.0K |
| May 20, 2026 | Hines Perry G. Director | Award | 2,780 | $130.0K |
| May 19, 2026 | ZURAITIS MARITA President & CEO | Sale 10b5-1 plan | 14 | $646 |
| May 6, 2026 | ZURAITIS MARITA President & CEO | Sale 10b5-1 plan | 2 | $92 |
| May 5, 2026 | ZURAITIS MARITA President & CEO | Sale 10b5-1 plan | 403 | $18.5K |
| May 4, 2026 | ZURAITIS MARITA President & CEO | Sale 10b5-1 plan | 266 | $12.3K |
| May 1, 2026 | ZURAITIS MARITA President & CEO | Sale 10b5-1 plan | 6,815 | $314.6K |
| Apr 23, 2026 | ZURAITIS MARITA President & CEO | Sale 10b5-1 plan | 7,500 | $346.2K |
| Apr 1, 2026 | McClure Beverley J. Director | Sale 10b5-1 plan | 1,081 | $46.0K |
| Mar 26, 2026 | Chauby Steven R Chief Marketing Officer | Purchase | 180 | $7.6K |
| Mar 4, 2026 | ZURAITIS MARITA President & CEO | Award | 63,056 | $0 |
| Mar 4, 2026 | ZURAITIS MARITA President & CEO | Award | 21,957 | $0 |
| Mar 4, 2026 | Fulks Stephanie A Senior Vice President | Award | 2,677 | $0 |
| Mar 4, 2026 | Fulks Stephanie A Senior Vice President | Award | 2,583 | $0 |
| Mar 4, 2026 | Desrochers Mark R Senior Vice President | Award | 3,826 | $0 |
| Mar 4, 2026 | Temchuk Maureen Amanda Controller & Chief Accting Off | Award | 1,149 | $0 |
| Mar 4, 2026 | Carley Donald M General Counsel | Award | 6,146 | $0 |
| Mar 4, 2026 | Carley Donald M General Counsel | Award | 2,295 | $0 |
| Mar 4, 2026 | Greenier Ryan E EVP & Chief Financial Officer | Award | 3,687 | $0 |
| Mar 4, 2026 | Greenier Ryan E EVP & Chief Financial Officer | Award | 2,526 | $0 |
| Mar 4, 2026 | Chauby Steven R Chief Marketing Officer | Award | 1,858 | $0 |
| Mar 4, 2026 | Chauby Steven R Chief Marketing Officer | Award | 2,583 | $0 |
| Mar 4, 2026 | Sanders Derik Tyson Senior Vice President | Award | 1,913 | $0 |
| Mar 4, 2026 | Sanders Derik Tyson Senior Vice President | Award | 2,295 | $0 |
| Mar 4, 2026 | Jackson Vanessa A Senior Vice President | Award | 2,868 | $0 |
| Mar 4, 2026 | McGinnis Jennifer L Vice President | Award | 1,722 | $0 |
| Feb 25, 2026 | Fetter Victor Director | Purchase | 3,500 | $149.5K |
| Jan 2, 2026 | McClure Beverley J. Director | Sale 10b5-1 plan | 1,081 | $48.8K |
| Jan 2, 2026 | ZURAITIS MARITA President & CEO | Sale 10b5-1 plan | 5,000 | $225.8K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for HORACE MANN EDUCATORS CORP /DE/
Free account. Everything above stays public.
Write why you follow HORACE MANN EDUCATORS CORP /DE/ and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading